This episode of the Pharmaron DMPK Insights Podcast Series sees Professor Ian Wilson (Professor in the Department of Metabolism, Digestion and Reproduction at Imperial College) take the listener on a fascinating journey into the link between carboxylic acid-containing drugs and their role in DILI.
Professor Wilson is a globally recognized and leading expert in drug metabolism, with more than 500 publications in the field, and this podcast will particularly focus on his latest paper, ‘Minimizing the DILI potential of carboxylic acid-containing drugs: a perspective’.
The episode also explores a range of other key topics, including:
- Whether acyl glucuronides are disproportionately blamed for DILI
- Other potential causes or sources of DILO
- Potential risk mitigation strategies for the reduction of DILI with these chemotypes
Acknowledgments
Produced from materials originally authored by Pharmaron Beijing Co., Ltd.
About Pharmaron
Pharmaron (Stock Code: 300759.SZ/3759.HK) is a premier R&D service provider for the life sciences industry. Founded in 2004, Pharmaron has invested in its people and facilities, and established a broad spectrum of research, development and manufacturing service capabilities throughout the entire drug discovery, preclinical and clinical development process across multiple therapeutic modalities, including small molecules, biologics and CGT products. With over 17,000 employees, and operations in China, the U.S., and the U.K., Pharmaron has an excellent track record in the delivery of R&D solutions to its partners in North America, Europe, Japan and China.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.